Research progress
FDA approves Sunharbo to help prevent another stroke in certain adults
The FDA approved Sunharbo for certain adults after stroke or high-risk TIA. Trial results show fewer ischemic strokes, with bleeding risks to consider.
AI-assisted summary and sourcing. Official and research sources are linked below; this article is informational and is not personal medical advice.
CareNews
Key takeaways
- The approval covers a defined group after stroke or high-risk TIA, not every stroke survivor or atrial fibrillation.
- Ischemic stroke occurred in 6.2% of participants receiving asundexian versus 8.4% receiving placebo; both groups received antiplatelet therapy.
- Overall major bleeding was similar between groups, but important bleeding risks remain.
A new approval, not a new recovery study
Sunharbo inhibits factor XIa, a protein involved in blood clotting. Antiplatelet medicines help keep platelets from sticking together to form clots. The FDA approval concerns preventing another stroke, rather than measuring recovery after one. It does not include an approval for atrial fibrillation.
Sources for this section: FDA — Sunharbo approval announcement, ClinicalTrials.gov — OCEANIC-STROKE, NCT05686070 (last update)
What the trial found
OCEANIC-STROKE was a phase 3, randomized, double-blind, placebo-controlled trial involving 12,327 people. Both groups received antiplatelet therapy. The primary publication appeared on April 16, 2026; the November news is the FDA approval, not a newly published trial.
The published abstract reports ischemic stroke in 6.2% of the asundexian group versus 8.4% of the placebo group. The FDA reports a 26% relative reduction. This is not a 26-percentage-point drop, a cure, or a guaranteed benefit for an individual.
Sources for this section: FDA — Sunharbo approval announcement, The New England Journal of Medicine — OCEANIC-STROKE abstract via PubMed, ClinicalTrials.gov — OCEANIC-STROKE, NCT05686070 (last update)
Safety remains part of the story
The FDA reports similar overall major bleeding between groups, but more major bleeding in people older than 75 and during the first 90 days. Gastrointestinal bleeding was more frequent, and diarrhea was a common side effect. Drug interactions and liver-related restrictions are also important limitations.
Sources for this section: FDA — Sunharbo approval announcement, The New England Journal of Medicine — OCEANIC-STROKE abstract via PubMed
Sources